Glaukos Corp. Files 10-Q for Period Ending March 31, 2024

TL;DR

<b>Glaukos Corp. has filed its Q1 2024 10-Q report detailing financial performance and operational data.</b>

AI Summary

GLAUKOS Corp (GKOS) filed a Quarterly Report (10-Q) with the SEC on May 3, 2024. Glaukos Corp. filed a 10-Q report for the period ending March 31, 2024. The filing covers financial information for the first quarter of 2024. Key financial statement data points are included in the filing. The company operates in the Surgical & Medical Instruments & Apparatus industry. The filing was made on May 3, 2024.

Why It Matters

For investors and stakeholders tracking GLAUKOS Corp, this filing contains several important signals. This 10-Q provides investors with the latest quarterly financial results, enabling them to assess the company's performance and financial health. The detailed financial statements and disclosures offer insights into revenue streams, expenses, and balance sheet items, crucial for investment decisions.

Risk Assessment

Risk Level: medium — GLAUKOS Corp shows moderate risk based on this filing. The filing is a standard quarterly report (10-Q), which is routine for public companies and does not inherently signal significant positive or negative events, but it does contain detailed financial information that requires careful analysis.

Analyst Insight

Review the detailed financial statements and segment performance within the 10-Q to understand revenue drivers and profitability trends for Q1 2024.

Revenue Breakdown

Key Numbers

• 2024-03-31 — Period of Report (Conformed Period of Report)
• 2024-05-03 — Filing Date (Filed as of Date)
• 2024-01-01 — Q1 2024 Start Date (Reporting period for Q1 2024)
• 2023-03-31 — Q1 2023 End Date (Comparative period for Q1 2023)

Key Players & Entities

• GLAUKOS Corp (company) — Filer name
• 0001192448 (company) — Central Index Key
• DE (company) — State of Incorporation
• ALISO VIEJO (company) — Business Address City
• CA (company) — Business Address State
• 92656 (company) — Business Address ZIP
• 949-367-9600 (company) — Business Phone
• 2024-05-03 (date) — Filing Date

FAQ

Key Dates

• 2024-03-31: End of Reporting Period — Marks the end of the first quarter of 2024 for financial reporting.
• 2024-05-03: Filing Date — Date the 10-Q report was officially submitted to the SEC.

Key Financial Figures

• $0.001 — hares of the registrant's Common Stock, $0.001 par value per share, outstanding. Tab

Filing Documents

• gkos-20240331x10q.htm (10-Q) — 1752KB
• gkos-20240331xex10d1.htm (EX-10.1) — 31KB
• gkos-20240331xex31d1.htm (EX-31.1) — 16KB
• gkos-20240331xex31d2.htm (EX-31.2) — 17KB
• gkos-20240331xex32d1.htm (EX-32.1) — 7KB
• gkos-20240331xex32d2.htm (EX-32.2) — 8KB
• 0001558370-24-006573.txt (&nbsp;) — 7856KB
• gkos-20240331.xsd (EX-101.SCH) — 44KB
• gkos-20240331_cal.xml (EX-101.CAL) — 73KB
• gkos-20240331_def.xml (EX-101.DEF) — 157KB
• gkos-20240331_lab.xml (EX-101.LAB) — 430KB
• gkos-20240331_pre.xml (EX-101.PRE) — 300KB
• gkos-20240331x10q_htm.xml (XML) — 1561KB

: FINANCIAL INFORMATION

PART I : FINANCIAL INFORMATION 6 Item 1.

Financial Statements

Financial Statements 6 Condensed Consolidated Balance Sheets 6 Condensed Consolidated Statements of Operations 7 Condensed Consolidated Statements of Comprehensive Loss 8 Condensed Consolidated Statements of Stockholders' Equity 9 Condensed Consolidated Statements of Cash Flows 10 Notes to Condensed Consolidated Financial Statements 11 Item 2.

Management's Discussion and Analysis of Financial Condition and Results of Operations

Management's Discussion and Analysis of Financial Condition and Results of Operations 26 Item 3.

Quantitative and Qualitative Disclosures About Market Risk

Quantitative and Qualitative Disclosures About Market Risk 35 Item 4.

Controls and Procedures

Controls and Procedures 35

: OTHER INFORMATION

PART II : OTHER INFORMATION 37 Item 1.

Legal Proceedings

Legal Proceedings 37 Item1A.

Risk Factors

Risk Factors 37 Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 52 Item 5. Other Information 52 Item 6. Exhibits 53

SIGNATURES

SIGNATURES 54 2 Table of Contents Note Regarding Forward-Looking Statements This report contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended (Securities Act), and Section 21E of the Securities Exchange Act of 1934, as amended (Exchange Act) All statements other than statements of historical or current facts included in this report are forward-looking statements. In some cases, you can identify forward-looking statements by the following words: "may," "will," "could," "would," "should," "expect," "intend," "plan," "anticipate," "believe," "estimate," "predict," "project," "potential," "continue," "ongoing" or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. Any statements in this Quarterly Report on Form 10-Q regarding future operations, including our expectations for future expenses, capital expenditures and income, our expectations regarding the impact of the macroeconomic environment, our strategy for growth, product development activities, the impact of the regulatory environment, including the timing and likelihood of regulatory approvals and the impact of new or changing regulations and pricing, and market position are forward-looking statements. These forward-looking statements are based on management's beliefs and assumptions based on the information available to management at the time of this report. Although we believe that we have a reasonable basis for each forward-looking statement contained in this report, we caution you that these forward-looking statements involve risks, uncertainties and other factors that may cause actual results, levels of activity, performance or achievements to be materially different from the information expressed or implied by these forward-looking statements. You are urged to carefully review the disclosures we make concerning the risks we face and other factors that may affect the o

- FINANCIAL INFORMATION

PART I - FINANCIAL INFORMATION

Financial Statements

Item 1. Financial Statements GLAUKOS CORPORATION CONDENSED CONSOLIDATED BALANCE SHEETS (in thousands, except par values) March 31, December 31, 2024 2023 (unaudited) Assets Current assets: Cash and cash equivalents $ 42,495 $ 93,467 Short-term investments 230,365 201,964 Accounts receivable, net 46,545 39,850 Inventory 50,185 41,986 Prepaid expenses and other current assets 19,020 18,194 Total current assets 388,610 395,461 Restricted cash 5,856 5,856 Property and equipment, net 101,858 103,212 Operating lease right-of-use assets 26,683 27,146 Finance lease right-of-use asset 43,575 44,180 Intangible assets, net 281,919 282,956 Goodwill 66,134 66,134 Deposits and other assets 18,703 15,469 Total assets $ 933,338 $ 940,414 Liabilities and stockholders' equity Current liabilities: Accounts payable $ 12,752 $ 13,440 Accrued liabilities 59,486 60,574 Total current liabilities 72,238 74,014 Convertible senior notes 283,117 282,773 Operating lease liability 30,110 30,427 Finance lease liability 70,289 70,538 Deferred tax liability, net 7,144 7,144 Other liabilities 19,710 13,752 Total liabilities 482,608 478,648 Commitments and contingencies (Note 12) Stockholders' equity: Preferred stock, $ 0.001 par value; 5,000 shares authorized; no shares issued or outstanding - - Common stock, $ 0.001 par value; 150,000 shares authorized; 49,875 and 49,148 shares issued and 49,847 and 49,120 shares outstanding as of March 31, 2024 and December 31, 2023, respectively 50 49 Additional paid-in capital 1,089,280 1,059,751 Accumulated other comprehensive income 1,437 1,165 Accumulated deficit ( 639,905 ) ( 599,067 ) Less treasury stock ( 28 shares as of March 31, 2024 and December 31, 2023) ( 132 ) ( 132 ) Total stockholders' equity 450,730 461,766 Total liabilities and stockholders' equity $ 933,338 $ 940,4

View Full Filing

View this 10-Q filing on SEC EDGAR